콘텐츠로 건너뛰기
Merck
  • LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation.

LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation.

RNA biology (2011-05-03)
Jessica M Silva, Nicole J Boczek, Michael W Berres, Xinghong Ma, David I Smith
초록

More than 98% of the human genome is comprised of non-protein coding sequences. Interestingly, a considerable fraction of these sequences is transcribed into non-protein coding RNA transcripts. These transcripts range in size from very small RNAs such as the miRNAs (20-25 base pairs) to transcripts that can range up to 100 kb or more. Some longer non-coding RNAs (lncRNAs) have been found to play important regulatory roles within cells. In this report, we demonstrate that LSINCT5 is a 2.6 Kb polyadenylated, long stress-induced non-coding transcript that is on the negative strand, localized in the nucleus and potentially transcribed by RNA polymerase III. LSINCT5 is overexpressed in breast and ovarian cancer cell lines and tumor tissues, relative to their normal counterpart. In addition, knocking down the expression of LSINCT5 in cancer-derived cell lines causes a decrease in cellular proliferation. Finally, we identified 95 genes with more than 2-fold changes when knocking down LSINCT5 expression by using the Affymetrix U133 Plus 2 array. We chose a subset of these genes to validate using qPCR and found that ten of these genes were indeed significantly affected by the LSINCT5 knockdown. Interestingly, two genes that were significantly downregulated were the lncRNA NEAT-1 and a protein coding gene PSPC1. We have therefore characterized a novel lncRNA that is overexpressed in breast and ovarian cancers, enhances cellular proliferation and may play a significant role in multiple processes.

MATERIALS
제품 번호
브랜드
제품 설명

Sigma-Aldrich
RNA Polymerase III Inhibitor, RNA Polymerase III Inhibitor, CAS 577784-91-9, is a cell-permeable inhibitor of RNA Polymerase III (IC₅₀ = 27 and 32 µM for human and S. cerevisiae RNA Pol III, respectively).